Atnaujinkite slapukų nuostatas

El. knyga: Prostate Cancer: Translational and Emerging Therapies

Edited by , Edited by
  • Formatas: 330 pages
  • Išleidimo metai: 19-Apr-2016
  • Leidėjas: CRC Press Inc
  • Kalba: eng
  • ISBN-13: 9781040212639
Kitos knygos pagal šią temą:
Prostate Cancer: Translational and Emerging TherapiesDidesnis paveikslėlis
  • Formatas: 330 pages
  • Išleidimo metai: 19-Apr-2016
  • Leidėjas: CRC Press Inc
  • Kalba: eng
  • ISBN-13: 9781040212639
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Scientists have reached a critical point in the development of new therapies for prostate cancer. The information gleaned from the Human Genome Project, alongside the emergence of new technologies for the use of genetic data has expanded the physician's understanding of disease progression and widened his armamentarium for prostate cancer prevention and control. This expertly-written reference thoroughly analyzes the scientific principles and methodologies behind the most recent translational therapies and provides the necessary context, data, and studies for practitioners to select appropriate candidates for treatment and effectively apply new therapies in clinical practice.
Preface iii
Contributors xiii
1. The Molecular Pathogenesis and Pathophysiology of Prostate Cancer
1(26)
William G. Nelson and Angelo M. De Marzo Introduction
1(26)
Anatomy and Function of the Human Prostate
1(2)
The Cellular Origin of Prostate Cancer
3(1)
Genetic Susceptibility to Prostate Cancer
4(2)
Epidemiology of Prostate Cancer
6(1)
Inflammation and Prostate Cancer
7(1)
Somatic Genome Changes in Prostate Cancer Cells
8(3)
Gene Expression Changes in Prostate Cancer
11(1)
Prostate Cancer Progression to Metastasis
12(1)
Conclusions
13(1)
References
13(14)
2. Targeted Therapies for Cancer: Definitions and Attributes
27(12)
Edward A. Sausville
Empirical vs. Targeted Agents for Cancer
27(2)
Qualification of Cancer Targets
29(1)
Agent/Target Discovery Strategies
30(1)
Pathogenic Targets: Issues
31(1)
Ontogenic Targets: Issues
32(1)
Pharmacological Targets: Issues
32(1)
Stromal Targets: Issues
32(1)
Targeted Therapeutics: Differences In Development Strategy
33(3)
Special Issues with Prostate Cancer
36(1)
References
37(2)
3. Novel Biomarkers for Disease Diagnosis, Prognosis, and Prediction
39(20)
James V. Tricoli
Introduction
39(1)
A Brief History of Prostate Cancer Diagnostics
39(1)
Genes and Proteins Correlating with Prostate Cancer
40(1)
Criteria for Biomarker Selection
41(4)
Prostate Cancer Biomarkers of Interest
45(5)
Future Directions
50(1)
References
51(8)
4. The Endothelin Pathway and its Modulation in Prostate Cancer
59(16)
Antonio Jimeno and Michael Carducci
Introduction
59(1)
The Endothelin Axis
59(5)
Leading Compound in Cancer: Atrasentan
64(5)
Other Compounds Undergoing Evaluation in Cancer: ZD4054
69(1)
Conclusions
69(2)
Summary
71(1)
References
71(4)
5. Targeting Extracellular Molecules in Prostate Cancer—Mechanisms to Inhibit Entry into the Cell-Signaling Abyss
75(16)
Susan F. Slovin
Introduction
75(1)
Potential Role of Cluster-Defined Molecules
76(2)
PSCA—What Role does it Play as a Cell
Surface Molecule?
78(1)
Mediators of Receptor Tyrosine Kinase Pathways
79(2)
Platelet-Derived Growth Factor as a Target for Therapy
81(1)
Inhibitors of PDGFR
82(1)
Targets of Immunologic Recognition: Enhancing immunogenicity Through Vaccines by Enhancing T cell function
82(1)
Studies in Men
83(1)
Manipulation of the T Cell—Can Changing Expression of Cell Surface Molecules Affect Function?
84(1)
Conclusions
85(1)
References
85(6)
6. Immunologic Approaches to Prostate Cancer
91(12)
Lawrence Fong and Eric J. Small
Introduction
91(1)
Detecting Responses to Immunotherapy
92(1)
Prostate Antigens Recognized by T-Cells
93(2)
Prostate Antigens Targeted by Antibodies
95(2)
Tumor Vaccines Utilizing Prostate Cancer as a Source of Antigen
97(1)
Cytokine Therapy
98(1)
Immunomodulatory Treatment
98(1)
Future Directions
99(1)
References
99(4)
7. Gene Therapy and Novel Clinical Trial Design
103(24)
Henry T. Tsai and Jonathan W. Simons
Introduction
103(1)
Gene Vector
104(8)
Strategies in PCA Gene Therapy
112(3)
Combined Modalities
115(1)
Novel Clinical Trial Design
116(5)
Future Directions
121(1)
References
121(6)
8. Angiogenesis Inhibitors in Prostate Cancer
127(16)
William D. Figg, Michael C. Cox, Tania Alachalabi, and William L. Dahut
Introduction
127(1)
Biologic Control of Angiogenesis
127(1)
Proangiogenic Factors
128(1)
Hypoxia Inducible Factor-1
128(1)
Angiopoietin
128(1)
Platelet-Derived Growth Factor
128(1)
Vascular Endothelial Growth Factor
129(1)
Prostate Cancer and the Dependence on Angiogenesis
130(1)
Anti-angiogenic Therapy for Prostate Cancer
131(1)
TNP-470
131(1)
Carboxytriamidazole (CAI)
132(1)
SU5416
132(1)
SU101
132(1)
2-Methoxyestradiol (Panzam, 2ME2)
132(1)
Imatinib
132(1)
Bevacizumab (rhuMab.VEGF)
133(1)
Thalidomide
133(1)
Single-Agent Thalidomide
134(1)
Thalidomide in Combination with Anticancer Agents
134(1)
Summary and Future Directions
135(1)
References
135(8)
9. What Antisense Oligonucleotides Have Promise in Prostate Cancer
143(20)
Kim N. Chi and Martin E. Gleave
Introduction
143(1)
Antisense Oligonucleotides
143(3)
ASOs in Prostate Cancer
146(8)
Summary
154(1)
References
155(8)
10. Novel Approaches to Androgen Receptor Blockade 163(16)
Ingo K. Mellinghoff
Introduction
163(1)
The Structural Basis of AR Function
163(2)
Activation of AR Signaling
165(2)
Mechanisms of Hormone-refractory Prostate Cancer Growth
167(3)
Therapeutic Implications
170(1)
References
171(8)
11. Can Post-Transcription Modifiers Change the Course of Prostate Cancer? 179(16)
David Z. Qian and Roberto Pili
Introduction
179(1)
Targeting MRNA
179(3)
Targeting Protein Synthesis
182(1)
Targeting Protein Modification
183(7)
Conclusions and Future Perspectives
190(1)
References
191(4)
12. Telomere Targeting Agents 195(14)
Angelika M. Burger and Lloyd R. Kelland
Introduction
195(5)
Telomerase and Telomeres in Prostate Cancer Development
200(2)
TTA and Prostate Cancer
202(3)
Future and Clinical Perspectives
205(1)
References
206(3)
13. Expanding the Role of EGFR Inhibitors in Prostate Cancer 209(14)
Srikala S. Sridhar and Malcolm J. Moore
Introduction
209(1)
EGFRs and Their Ligands
209(2)
EGFRs and Prostate Cancer
211(1)
Targeting the EGFR Family in Prostate Cancer
212(1)
Tyrosine Kinase Inhibitors
212(3)
Monoclonal Antibodies
215(2)
Discussion
217(1)
References
218(5)
14. Bone-Directed Therapy in Prostate Cancer: Rationale and Novel Approaches 223(14)
Colby L. Eaton, Kate D. Linton, and Freddie C. Hamdy
Abstract
223(1)
Primary Considerations in the Evaluation of New Treatments in Prostate Cancer
223(1)
Treatment of Established Bone Metastases: Targeting the "Vicious Cycle"
224(5)
Prevention of Metastasis: Targeting the Establishment of Bone Metastases
229(4)
Concluding Remarks
233(1)
References
233(4)
15. Inhibiting the Proteasome in Advanced Prostate Cancer 237(8)
Robert Dreicer
Overview of the Proteasome and Its Function
237(1)
Bortezomib
237(1)
Inhibiting the Proteasome in Prostate Cancer
238(1)
Clinical Experience of Bortezomib in Prostate Cancer
239(1)
Docetaxel + Bortezomib
240(2)
Summary
242(1)
References
242(3)
16. Hsp90: A Target for Prostate Cancer Therapy 245(12)
David B. Solit, Howard I. Scher, and Neal Rosen
Introduction
245(1)
AR Stability and Activity Are Regulated by HsP90
245(1)
HsP90 as a Target for Cancer Therapy: Basis for a Therapeutic Index
246(3)
Clinical Experience with 17-AAG
249(1)
Novel HsP90 Inhibitors That Bind the N-Terminal ATP Pocket
250(1)
HsP90 Inhibitors That Bind the C-Terminal Domain
251(1)
HDAC Inhibitors
251(1)
Conclusions
251(1)
References
252(5)
17. Vitamin D Analogs and Their Role in Prostate Cancer 257(24)
Tomasz M. Beer and Anne Myrthue
Introduction
257(1)
Epidemiology of Vitamin D and Prostate Cancer
257(1)
Mechanisms of Antineoplastic Activity in Preclinical Systems
258(3)
Vitamin D in Combination with Other Antineoplastic Agents in Preclinical Models
261(1)
Clinical Trials of Calcitriol in Prostate Cancer
262(4)
Calcitriol Analogs
266(2)
Conclusions
268(1)
References
268(13)
18. Other Novel Therapies 281(10)
Arif Hussain and Richard Schraeder
Introduction
281(1)
Epothilones
281(3)
Satraplatin
284(2)
Conclusion
286(1)
References
287(4)
19. Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer 291(24)
Michael J. Morris, Neeta Pandit-Taksar, Chaitanya Divgi, Steven Larson, and Howard I. Scher
Introduction
291(1)
Prostate Cancer, Standard Imaging, and Clinical Trial Design
292(4)
Tracers That Demonstrate Metabolism and Growth
296(6)
Imaging Individual Proteins Relevant to Prostate Cancer
302(3)
Summary and Future Directions
305(1)
References
306(9)
Index 315


Nancy A. Dawson, W. Kevin Kelly
Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97810402126396e.html
Raktažodžiai: